A Great Yarmouth mum was left using a wheelchair for nine years after a flesh-eating infection developed following a C-section.

KELLY Simmons was left wheelchair-bound for nine years after a flesh-eating bug infected her C-section scar, as a result of ...

A mother was separated from her newborn for three months after a flesh-eating infection attacked her caesarean section scar - ...

A mum was unable to see her baby for three months after a flesh-eating bug infected her c-section scar - leaving her using a ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...

InflaRx was founded in 2007 and maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan. In other recent news, InflaRx N.V. has disclosed post-hoc analyses indicating potential efficacy ...

Dr. Clarissa Souza, a board-certified veterinary dermatologist and head of the dermatology and otology service at the University of Illinois Veterinary Teaching Hospital in Urbana. Dr. Clarissa Souza, ...

If you're an existing patient of this provider, please use your U of U Health (MyChart) account to schedule your appointment. If you're having trouble signing in, need guidance on using U of U Health ...

Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum (PG) last year, the German drugmaker ended 2025 with a glimmer of hope for the ...

InflaRx ( (IFRX)) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...